In September 2025, iZafe Group AB, reg. no. 556762-3391 (“iZafe” or the “Company”), acquired the Dutch company Thuisapparatuur Nederland B.V. (“TAN”). iZafe has today entered into an addendum agreement with Stichting TCCN, the seller of TAN, under which the first partial payment for the acquisition, corresponding to a total of approximately EUR 310,000, will be paid in full through a new issue of a total of 10,386,409 B shares in iZafe at a subscription price of SEK 0.33 per B share.

The first partial payment for the acquisition relates to approximately EUR 170,000 in amortisation of loans from TAN to the seller, which were assumed by iZafe in connection with the acquisition. The remaining approximately EUR 140,000 relates to a partial payment of the purchase price for the acquisition. Following the first partial payment, EUR 1.24 million remains to be paid for the acquisition, of which approximately EUR 680,000 relates to repayment of assumed loans and approximately EUR 560,000 relates to the cash purchase price.

Payment of the remaining part of the acquisition will, as previously communicated, be made in six instalments during the period from 31 January 2027 to 31 July 2029, where the first instalment corresponds to 20 percent of the total amount and the remaining amount thereafter is distributed equally over the final five instalments.

The subscription price per B share amounts to approximately SEK 0.33, corresponding to the volume-weighted average price during the ten (10) trading days preceding the agreement date, with a discount of approximately 10.4 percent. Payment for the new B shares will be made in full by way of set-off against claims relating to the first partial payment for the acquisition of TAN.

The issue entails that the number of shares and votes in the Company increases by 10,386,409, from 430,591,337 shares, of which 600,000 are A shares, to 440,977,746 shares, of which 600,000 are A shares. The share capital increases by SEK 519,320.45, from SEK 21,529,566.85 to SEK 22,048,887.30. The issue entails a dilution effect of approximately 2.36 percent of the number of shares in the Company.

The issue will be resolved by the Board of Directors pursuant to the authorisation granted by the Annual General Meeting on 28 May 2026 and is expected to be completed no later than 31 July 2026.

Reasons for deviation from the shareholders’ preferential rights, etc.

The reason for deviating from the shareholders’ preferential rights is to carry out the first partial payment for the acquisition of TAN in a time- and cost-efficient manner without affecting the Company’s short-term liquidity position.

The Board of Directors has carefully considered alternative financing options, including carrying out a rights issue. Taking into account the limited size of the issue, the expected time required and the costs associated with alternative financing solutions, the Board of Directors has found that a directed new share issue to the seller is the most appropriate solution. The Board’s overall assessment is therefore that a directed issue is beneficial to both iZafe and its shareholders, and that the reasons for deviating from the shareholders’ preferential rights outweigh the reasons for carrying out a rights issue.

The subscription price has been agreed through arm’s length negotiations with the counterparty and is considered to be market-based, as it is based on the volume-weighted average price during the ten (10) trading days preceding the signing of the agreement, with an issue discount that is slightly lower than the issue discount applied in the Company’s most recent directed new share issue.

An Extraordinary General Meeting was held in iZafe Group AB, reg. no. 556762-3391 (the “Company”), on 12 March 2026 at the Company’s office. The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution of 19 February 2026 regarding a directed issue of up to 39,236,014 class B shares.

The directed share issue constitutes the second part of the capital raise that was announced through a press release on 19 February 2026.

The first part of the directed share issue, comprising 20,868,973 class B shares, which was resolved by the Board of Directors pursuant to the authorization granted by the General Meeting, has already been registered with the Swedish Companies Registration Office (Bolagsverket) and Euroclear Sweden AB.

Through the second part of the directed share issue, which was approved at today’s Extraordinary General Meeting, the Company’s share capital will increase by a maximum of SEK 1,961,800.70 through the issuance of up to 39,236,014 class B shares at a subscription price of SEK 0.33 per class B share.

In total, the Company will receive approximately SEK 19.8 million before transaction costs through the directed share issues.

Following registration of the second part of the directed share issue, which is expected to take place shortly, the number of shares in the Company will amount to 430,591,337 shares, divided into 600,000 class A shares and 429,991,337 class B shares. Following registration of the second part of the directed share issue, the Company’s share capital will amount to SEK 21,529,566.85.

iZafe Group AB (publ.) (the “Company”) announces that all participants in the Company’s long-term incentive program LTIP 2023 have exercised their Series A warrants for subscription of shares in the Company.

LTIP 2023 was approved by the extraordinary general meeting held on 21 December 2023 and comprised a total of 7,907,877 warrants, divided into three series (A–C). Through the exercise of Series A warrants, employees and key personnel within the Group have now subscribed for and paid for their shares in accordance with the terms and conditions of the program.

The Series A warrants under LTIP 2023 could only be exercised after a predefined share price target had been achieved. The share price target for Series A warrants corresponded to 250 percent of the average volume-weighted price of the Company’s B share during the period from 7 to 20 December 2023, amounting to SEK 0.66 per B share. The share price target for Series A has been met, as the average closing price during the ten trading days preceding the first day of subscription amounted to SEK 0.671, thereby exceeding the share price target. The share price targets established for Series B and Series C warrants have not been met, and the Series B and Series C warrants have therefore lapsed without being exercised.

The exercise of Series A warrants has been carried out at the quota value of SEK 0.05 per B share, resulting in total subscription proceeds of SEK 263,595.90 to the Company. Following registration, the number of B shares in the Company will increase by 5,271,918, corresponding to a dilution of approximately 1.40 percent of the voting rights and 1.42 percent of the total number of shares in the Company. The total number of shares will thereby increase from 365,214,432 to 370,486,350 and the share capital will increase from SEK 18,260,721.60 to SEK 18,524,317.50 following registration.

“Being able to complete the incentive program is both well-deserved and very positive. Over several years, our employees have demonstrated strong commitment and dedication, while also prioritizing the Company’s long-term development by accepting a demanding workload with significant responsibility. LTIP 2023 is therefore an important tool for creating shared ownership and a long-term incentive that keeps the organization motivated and invested in the Company’s continued journey. The Board views this as a key element in building further on the stable foundation now in place, where the progress made over time has gradually created a strong business pipeline and solid conditions for Dosell to become an increasingly natural choice for municipalities and other stakeholders going forward,” says Richard Wolff, Chairman of the Board of iZafe Group AB.

Registration of the new shares with the Swedish Companies Registration Office (Bolagsverket) and Euroclear Sweden AB is expected to be completed during December 2025.

iZafe Group AB (publ) announces today that the company is changing its Certified Adviser from Mangold Fondkommission AB to Carnegie Investment Bank AB (publ).

iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB regarding the role as Certified Adviser. Carnegie Investment Bank AB will assume the role of Certified Adviser on April 1, 2025. Until then, Mangold Fondkommission AB will continue to act as the company's Certified Adviser.

iZafe Group AB ("iZafe Group") today announces that Ida Almgren has decided to step down as Chief Financial Officer to explore new career opportunities.

During the transition period, Ida will actively assist iZafe Group to ensure a smooth transition, while a search process for a new CFO commences. Ida's last day of work will be June 18.

iZafe is deeply committed to a stable transition and to continuously delivering value to our shareholders and stakeholders. We are fully focused on executing our long-term strategy and realizing our business plans with precision and determination.

iZafe Group AB (publ.) presents today, August 25, its report for the second quarter.

Financial Performance in Summary

  • Net sales for the quarter amounted to SEK 403 (84) thousand, a growth of 380% compared to the corresponding quarter last year. The increase in turnover can partly be attributed to organic growth, partly to growth through acquisition, when Pilloxa was acquired in December 2022. Excluding the turnover from the acquired company, the growth amounted to 198%. The quarter’s turnover consists of income attributable to the sale of the digital pharmaceutical robot Dosell and the sale of the medical device Pilloxa. Pilloxa AB was acquired on 28 November 2022 and is therefore not included in the quarter’s turnover for the previous year.
  • Operating profit for the quarter amounted to SEK -5,097 (-5,184) thousand.
  • Profit after financial items for the quarter amounted to -5,136 (-5,233) TSEK.
  • Cash flow for the period amounted to SEK -3,496 (-7,155) thousand.
  • Earnings per share for the quarter before / after dilution amounted to SEK 0.0 (-0.1).
  • Equity per share amounted to SEK 0.2 (0.4) at the end of the period.
  • The equity ratio at the end of the period amounted to 82.4 (81.8) percent. 

 
Significant events during the quarter

  •  iZafe has signed a cooperation agreement with Spanish Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi’s minimum commitment over a four-year period is worth at least SEK 12 million.
  • iZafe has signed a cooperation agreement with MDM Pulse for the right to sell and market the medicine robot Dosell in Portugal. MDM Pulse’s minimum commitment over a five-year period amounts to SEK 12.2 million to subsequently generate a recurring license income of at least SEK 4.2 million annually.

Significant events after the end of the quarter

  •  iZafe successfully completed all necessary technical integrations and adaptations to launch Dosell on the Dutch market. The company will now deliver 50 units for testing. After successful testing, the remaining 1,000 units will be delivered successively during the year.

 
Comments from CEO
I am pleased to share with you the latest progress and developments in our company during the past quarter. Despite an initially low turnover, our focus on the right strategies and measures has resulted in a positive increase in our turnover. This increase, although it may be modest, marks a turning point in the right direction. Together with our continuous effort to streamline and reduce costs, we now stand on a stable foundation.
 
I feel confident that the liquidity we obtained in March will be sufficient to bring us to a cash flow positive position. Our determination to optimize our finances and capital utilization has set us on this promising path forward. I would like to express my heartfelt thanks to you for your continued trust and investment in our company. Your faith in us has been a decisive factor in our success.
 
During the first half of the year, we communicated about several significant orders that lie ahead. Now our top priority is to ensure that the deliveries of these orders are carried out smoothly. One of our most challenging tasks is to deliver 1,000 units to the Netherlands before the end of this year. The first 50 units will be used to guarantee a seamless customer experience with our innovative solution, uniquely tailored to the needs of the Dutch market. The setup is a result of our joint work with investments from both the partner, Dutch IVE Ventures, and us, where IVE Ventures invested in a comprehensive system where Dosell has a key function. Tests are currently underway and are expected to be completed shortly. When potentially needed fine adjustments in the customized system solution are in place after feedback from the tests, we will gradually deliver the remaining units according to plan.
 
We also see positive progress in Spain, where plans are progressing as previously communicated. During Q2, an agreement worth minimum SEK 12 million over four years was secured, including 1,800 Dosell units. The Spanish partner Ti-Medi delivers today solutions to facilitate correct medication to over 650 pharmacies in Spain and Portugal. During the autumn, we are working intensively to adapt Dosell and the customer journey for the Spanish market, which will hopefully lead to an extensive launch during the first quarter of 2024.
 
Also in Italy we have worked further to develop our collaborations. Our partner has been working for some time to achieve a wider acceptance of sachets in the Italian market. They are currently conducting a funding round to secure the necessary capital to accelerate sales of our pharmaceutical robots along with their innovative sachets on a larger scale.
 
In the UK, we are on the verge of completing our first pilot, which is a milestone for us. This marks the start of gradually increasing sales that are expected to pick up from the turn of the year. The UK is a market with huge potential, and we foresee steady growth as the market matures.
 
In our home region, the Nordics, our work with municipalities in Sweden and Norway has yielded results. The decision to expand the use of Dosell within these municipalities is a clear indication that our product is appreciated for its simplicity, functionality and its ability to relieve care by ensuring correct medication at the right time. I am optimistic that we will see increasing demand also here in the Nordics during the autumn, and a positive trend that is expected to grow significantly in the coming year.
 
Our latest acquisition, Pilloxa, has added additional value to our portfolio. Our focus now is on ensuring customer satisfaction through smooth deliveries and maximizing the potential of our new customers. Going forward, we aim to merge our concepts into a world-unique concept that can help the patient at all stages; regardless of how they manage their medication, but right now our primary focus is on ensuring that Dosell deliveries to our partners around Europe.
 
In summary, we are stronger and more well prepared than ever. With a stable liquidity that is expected to bring us to a cash flow positive position, together with the majority of orders received and a growing demand, we are enthusiastically looking forward to the upcoming autumn. I am convinced that, together with my amazing team, we will be able to achieve outstanding results.
 
Again, many thanks for your invaluable trust as a shareholder.
 
Anders Segerström
CEO, iZafe Group
                     
 

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders. Ti-Medi has in total acquired 12,529,309 shares at the price of SEK 0.29 per share through a block deal brokered by Mangold Fondkommission.

Ti-Medi is a global company active in the manufacturing and distribution of technical solutions for compliance in pharmaceutical management. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
For more information, see Ti-Medi's website, www.ti-medi.com/en.

"Our assessment is that the demand for iZafe Group's products and services will increase in the markets where we operate. We have long been looking for a company that develops and offers its customers precisely these types of services. Therefore, we have decided to invest in iZafe Group and we also hope to be able to find a good collaboration in the future to bring iZafe's products and services into Ti-Medi's product range in order to be able to offer these to our customers," says Marc Tarruell Tibau, co-founder of Ti-Medi

"The company has now gained a new strong and long-term owner that contributes with expertise and a global network. We view this very positively and interpret the investment as proof that iZafe Group's product and operations have support among knowledgeable market colleagues. We look forward to sharing the knowledge that Ti-Medi possesses about distribution in Southern Europe and initiating discussions about a future collaboration", says Anders Segerström, CEO of iZafe Group AB

Today, March 6, 2023, is the last day of trading with the warrants of series TO13B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO13B runs up until March 8, 2023. Each warrant of series TO13B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO13B is SEK 0.20 per share of series B.

If all the warrants of series TO13B are exercised, the Company will receive approximately SEK 23.7 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than March 8, 2023. Alternatively, the holder may sell the warrants, no later than today, March 6, 2023. Please be aware that certain nominees may close their subscriptions earlier than March 8, 2023. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate existing shareholders for the dilution from the directed issue of units, and with the purpose of capitalizing iZafe in a favorable way, the Company issued warrants of series TO13B free of charge to all shareholders. A total of 118,556,833 warrants of series TO13B were issued. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.20 per share of series B. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO13B shall correspond to 70 percent of the
volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period from and including February 9, 2023, up to and including February 22, 2023. However, not lower than the quota value for the Company's share, corresponding to SEK 0.20, and not higher than SEK 0.30 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.21. Thus, the subscription price is determined to SEK 0.20. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023. Complete terms and conditions for the warrants of series TO13B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.

"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:
• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.
• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.
• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.
With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.

Webbdesign av Comlog Webbyrå Stockholm